Core Viewpoint - The ongoing dispute over the exclusive agency rights for the "AestheFill" product between Aimeike and *ST Suwu has seen new developments, with a recent arbitration decision impacting sales and distribution rights in mainland China [1][2][3]. Summary by Relevant Sections Arbitration Decision - The emergency arbitrator's decision prohibits Korean REGEN Company (Aimeike's subsidiary) from independently selling "AestheFill" in mainland China until the arbitration outcome is determined [1]. - The decision also affirms that DaTou Medical (*ST Suwu's subsidiary) remains the exclusive distributor of AestheFill in mainland China [1][3]. Company Responses - An internal source from Aimeike clarified that the recent decision is not a final arbitration result but a preliminary measure to protect rights before the final ruling [2]. - *ST Suwu stated that REGEN must cease any other sales methods in mainland China, reinforcing their position as the exclusive distributor [3]. Financial Implications - *ST Suwu highlighted that losing the AestheFill rights could significantly impact their revenue, with projected sales of 326 million yuan in 2024, accounting for 20.42% of total revenue, and a gross profit of 269 million yuan, representing 34.80% of total gross profit [16]. - The first quarter of 2025 is expected to see AestheFill sales of 113 million yuan, making up 35.55% of total revenue and 45.77% of gross profit [16]. Product Background - AestheFill, known as "童颜针" (youthful needle), is a regenerative aesthetic injection agent used for filling and improving wrinkles, with a market price ranging from 19,800 yuan to 23,700 yuan per unit [16].